title: Genetic advances uncover mechanisms of chemotherapy-induced peripheral neuropathy.
abstract: Chemotherapy-induced peripheral neuropathy (CIPN) is a common dose-limiting toxicity experienced in 30-40% of patients undergoing treatment with various chemotherapeutics, including taxanes, vinca alkaloids, epothilones, proteasome inhibitors, and thalidomide. Importantly, CIPN significantly affects a patient's quality of life. Recent genetic association studies are enhancing our understanding of CIPN pathophysiology and serve as a foundation for identification of genetic biomarkers to predict toxicity risk and for the development of novel strategies for prevention and treatment.
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
authors.forename: K C
authors.initials: KC
authors.lastname: Chua
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
authors.forename: D L
authors.initials: DL
authors.lastname: Kroetz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D055808:Drug Discovery; D055106:Genome-Wide Association Study; D006801:Humans; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000235:genetics* / Q000503:physiopathology; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents